Robert Glassman
Director/Miembro de la Junta en PHARVARIS N.V. .
Fortuna: 643 676 $ al 31/05/2024
Perfil
Dr. Robert H.
Glassman is an Executive Vice President-Search & Evaluation at Enavate Sciences, an Independent Non-Executive Director at Jubilant Therapeutics, Inc., an Independent Director at Tarus Therapeutics, Inc., an Independent Non-Executive Director at Pharvaris NV, a Clinical Assistant Professor at Weill Cornell Medical College and an Independent Director at Portage Biotech, Inc. He is on the Board of Directors at Jubilant Therapeutics, Inc., Umoja Biopharma, Inc., Pharvaris GmbH, Tarus Therapeutics, Inc., Pharvaris NV and Portage Biotech, Inc. Dr. Glassman was previously employed as a Vice Chairman & Managing Director by Credit Suisse Securities (USA) LLC, a Managing Director by Bank of America Merrill Lynch (New York), a Venture Partner by OrbiMed Advisors Private Equity, a Principal by Merrill Lynch & Co., Inc. /Old/, a Consultant by McKinsey & Co., Inc., and a Basic Science Investigator by The Rockefeller University.
He received his undergraduate degree from Harvard College and a doctorate degree from Harvard Medical School.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
PHARVARIS N.V.
0.06% | 01/04/2024 | 33 352 ( 0.06% ) | 632 354 $ | 31/05/2024 |
PORTAGE BIOTECH INC
0.12% | 31/03/2023 | 23 637 ( 0.12% ) | 11 322 $ | 31/05/2024 |
Cargos activos de Robert Glassman
Empresas | Cargo | Inicio |
---|---|---|
PHARVARIS N.V. | Director/Miembro de la Junta | 01/01/2021 |
PORTAGE BIOTECH INC. | Director/Miembro de la Junta | 01/07/2022 |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | Director/Miembro de la Junta | 01/01/2021 |
Pharvaris GmbH
Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Director/Miembro de la Junta | 05/01/2021 |
Umoja Biopharma, Inc.
Umoja Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Umoja Biopharma, Inc. engages in the development of immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. It offers an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies that attack cancer cells. The company was founded by Michael Jensen, Philip Low, Andy Scharenberg and Ryan Crisman and is headquartered in Seattle, WA. | Director/Miembro de la Junta | 25/01/2021 |
Jubilant Therapeutics, Inc.
Jubilant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Jubilant Therapeutics, Inc. operates as a patient-centric biopharmaceutical company. The firm uses advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. The company is headquartered in Bedminster, NJ. | Director/Miembro de la Junta | 01/02/2021 |
Weill Cornell Medical College | Corporate Officer/Principal | - |
Enavate Sciences
Enavate Sciences Financial ConglomeratesFinance Enavate Sciences is a platform created by Patient Square Capital that supports therapeutic companies advancing medicines and enabling technologies to address patient needs. Enavate Sciences is based in New York, NY. The company provides capital support and operational experience to a diverse portfolio of therapeutics companies, aiming to accelerate innovation. James P. Boylan has been the CEO of the company since 2022. | Inversor de Capital Privado | 11/07/2022 |
Antiguos cargos conocidos de Robert Glassman.
Empresas | Cargo | Fin |
---|---|---|
Credit Suisse Securities (USA) LLC
Credit Suisse Securities (USA) LLC Regional BanksFinance Credit Suisse Securities (USA) LLC provides a variety of capital raising, market making, advisory and brokerage services for governments, financial institutions, high-net-worth individuals, and corporate clients and affiliates. It is also a primary dealer in U.S. government securities and an underwriter, placement agent, and dealer for money market instruments, commercial paper, mortgage and other assetbacked securities, as well as a range of debt, equity and other convertible securities of corporations and other issuers. The company was founded on January 3, 2003 and is headquartered in New York, NY. | Director/Miembro de la Junta | 01/01/2021 |
░░░░ ░░ ░░░░░░░ ░░░░░░░ ░░░░░ ░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░ ░░░░░ ░░░░ ░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░░░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
░░░░░░░░ ░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formación de Robert Glassman.
Harvard Medical School | Doctorate Degree |
Harvard College | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
PHARVARIS N.V. | Health Technology |
PORTAGE BIOTECH INC. | Health Technology |
Empresas privadas | 10 |
---|---|
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Finance |
Merrill Lynch & Co., Inc. /Old/
Merrill Lynch & Co., Inc. /Old/ Investment Banks/BrokersFinance Merrill Lynch & Co., Inc. provided wealth management, securities trading and sales, corporate finance and investment banking services. Merrill Lynch was a global trader and underwriter of securities and derivatives across a range of asset classes and serve as a strategic advisor to governments, institutions and individuals worldwide. The company was founded in 1913 and was headquartered in Charlotte, NC. | Finance |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | Health Technology |
Pharvaris GmbH
Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Health Technology |
Credit Suisse Securities (USA) LLC
Credit Suisse Securities (USA) LLC Regional BanksFinance Credit Suisse Securities (USA) LLC provides a variety of capital raising, market making, advisory and brokerage services for governments, financial institutions, high-net-worth individuals, and corporate clients and affiliates. It is also a primary dealer in U.S. government securities and an underwriter, placement agent, and dealer for money market instruments, commercial paper, mortgage and other assetbacked securities, as well as a range of debt, equity and other convertible securities of corporations and other issuers. The company was founded on January 3, 2003 and is headquartered in New York, NY. | Finance |
Bank of America Merrill Lynch (New York) | |
Umoja Biopharma, Inc.
Umoja Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Umoja Biopharma, Inc. engages in the development of immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. It offers an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies that attack cancer cells. The company was founded by Michael Jensen, Philip Low, Andy Scharenberg and Ryan Crisman and is headquartered in Seattle, WA. | Health Technology |
Jubilant Therapeutics, Inc.
Jubilant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Jubilant Therapeutics, Inc. operates as a patient-centric biopharmaceutical company. The firm uses advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. The company is headquartered in Bedminster, NJ. | Health Technology |
Enavate Sciences
Enavate Sciences Financial ConglomeratesFinance Enavate Sciences is a platform created by Patient Square Capital that supports therapeutic companies advancing medicines and enabling technologies to address patient needs. Enavate Sciences is based in New York, NY. The company provides capital support and operational experience to a diverse portfolio of therapeutics companies, aiming to accelerate innovation. James P. Boylan has been the CEO of the company since 2022. | Finance |
- Bolsa de valores
- Insiders
- Robert Glassman